Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Arixtra® (fondaparinux) – New indication
December 23, 2024 - The FDA approved Mylan’s Arixtra (fondaparinux), for the treatment of venous thromboembolism (VTE) in pediatric patients aged 1 year or older weighing at least 10 kg.
